Implementation of Injectable Cabotegravir/Rilpivirine for Treatment of Human Immunodeficiency Virus in Patients With Substance Use Disorders at a Syringe Exchange Clinic.

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2024-10-23 eCollection Date: 2024-11-01 DOI:10.1093/ofid/ofae640

Amanda Perez, Shane Nieves, Jessica Meisner

引用次数: 0

Abstract

Cabotegravir + rilpivirine (CAB + RPV-LA) is a long-acting antiretroviral therapy (ART) that can be utilized for people with human immunodeficiency virus (HIV) who face barriers to daily ART. Here, we describe the implementation of a program that provides low-barrier access to CAB + RPV-LA for people with HIV and opioid use disorder at a syringe exchange.

查看原文本刊更多论文

在一家注射器交换诊所实施注射用卡博替拉韦/利匹韦林治疗药物使用障碍患者的人类免疫缺陷病毒。

卡博替拉韦+利匹韦林（CAB + RPV-LA）是一种长效抗逆转录病毒疗法（ART），可用于那些面临日常抗逆转录病毒疗法障碍的人类免疫缺陷病毒（HIV）感染者。在此，我们介绍了一项计划的实施情况，该计划为注射器交换所中的艾滋病病毒感染者和阿片类药物使用障碍患者提供低门槛的 CAB + RPV-LA 治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.